Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Brain Inflammation in Stroke Patients Using Ficolin-2, Gadoteric Acid, and 18F-DPA-714

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying inflammation in the brain and blood vessels in patients who have experienced a stroke or a transient ischemic attack (often called a mini-stroke). The study is particularly interested in a condition known as carotid stenosis, which is a narrowing of the carotid arteries that supply blood to the brain. The trial will use a special imaging technique called PET/MRI to look at inflammation in the brain and carotid arteries. Two substances will be used in this study: Gadoteric Acid, which is a type of contrast used in imaging, and 18F-DPA-714, a compound that helps highlight inflammation during the imaging process.

The purpose of the study is to explore the relationship between levels of a protein called ficolin-2 in the blood and inflammation in the brain and carotid arteries. Participants will undergo imaging with PET/MRI to assess inflammation. The study will involve taking blood samples to measure ficolin-2 levels and performing imaging tests to observe the condition of the carotid arteries and brain. The imaging will help identify features such as the size of any brain infarcts (areas of tissue damage due to lack of blood flow) and any changes in the carotid arteries, such as the presence of bleeding within the artery walls or damage to the protective layer of the artery.

Throughout the study, participants will have their blood tested and undergo imaging at specific times to monitor changes. The study aims to provide insights into how ficolin-2 levels relate to inflammation in the brain and carotid arteries, which could help improve understanding and treatment of conditions like stroke and transient ischemic attack. The trial is expected to continue until the end of 2024.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide a signed written informed consent. This is a document that confirms your agreement to participate in the study after understanding all the details and potential risks involved.

  2. Step 2

    Initial assessment

    You will undergo an initial assessment to confirm your eligibility. This includes verifying that you are 18 years or older and have experienced a probable transient ischemic attack (TIA) or ischemic stroke within the last 24 hours. Additionally, the presence of atherosclerotic carotid stenosis between 50% and 99% will be confirmed through imaging tests such as Doppler ultrasound, MR angiography, CT angiography, or catheter angiography.

  3. Step 3

    Medication administration

    During the trial, you will receive two types of medications: gadoteric acid and 18F-DPA-714. These will be administered through an injection into your vein (intravenous use). The specific dosage and frequency will be determined by the study team based on your individual needs.

  4. Step 4

    Imaging and blood tests

    On day 5 of the trial, you will undergo a PET/MRI scan. This imaging test will help assess inflammation in your carotid arteries and brain. Additionally, a blood sample will be taken to measure the levels of a protein called ficolin-2 in your plasma.

  5. Step 5

    Follow-up assessments

    Further assessments will be conducted on day 15. These will include additional blood tests to measure ficolin-2 levels and evaluations of morphological data from the imaging tests. The results will help determine the presence of specific conditions such as intraplaque hemorrhage and infarct size.

  6. Step 6

    Completion of the trial

    The trial is expected to conclude by December 1, 2024. Upon completion, you will receive information about the findings and any relevant follow-up care that may be necessary.

Who can join the trial?

4 criteria

  • Patients must be 18 years or older.
  • Patients must provide signed written informed consent before any study-specific procedures.
  • Patients must have had a probable ipsilateral transient ischemic attack (TIA) or an ischemic stroke within 24 hours from the onset. A TIA involves a temporary problem with speech, movement, or vision that lasts less than 24 hours and is related to a carotid artery.
  • Patients must have atherosclerotic carotid stenosis between 50% and 99%. This means there is a narrowing of the carotid artery due to plaque buildup, confirmed by imaging tests like Doppler ultrasound, MR angiography, CT angiography, or catheter angiography after the TIA or stroke.

Who cannot join the trial?

1 criterion

  • Patients who have had a **stroke** or **transient ischemic attack** (a temporary blockage of blood flow to the brain) cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

[18F]DPA-714 is a special type of imaging agent used in this clinical trial. It helps doctors see inflammation in the brain and carotid arteries using a PET/MRI scan. This imaging agent is particularly useful for patients who have had a transient ischemic attack or an acute ischemic stroke due to carotid stenosis. By using this agent, doctors can better understand the level of inflammation in these areas, which is important for assessing the patient's condition and planning further treatment.

What is already known about the treatment

Ficolin-2 – Ficolin-2 is not a medication but a protein being studied for its potential role in medical conditions like stroke or transient ischemic attack. It is currently under investigation in clinical trials to understand its association with inflammation in the brain and carotid arteries, which are important in these conditions. The research aims to see if levels of ficolin-2 in the blood are linked to inflammation detected by advanced imaging techniques. This protein is part of the body's immune system and may help in identifying or managing inflammation related to strokes.

Investigated diseases

  • Transient Ischemic Attack

    A transient ischemic attack (TIA) is a temporary period of symptoms similar to those of a stroke. It occurs when there is a brief interruption in the blood supply to part of the brain. This interruption can cause sudden numbness or weakness, especially on one side of the body, confusion, trouble speaking, or difficulty understanding speech. The symptoms usually last for a few minutes to a few hours and then resolve completely. Unlike a stroke, a TIA does not cause permanent damage to the brain. It is often considered a warning sign of a potential future stroke.

  • Acute Ischemic Stroke

    An acute ischemic stroke occurs when a blood clot blocks or narrows an artery leading to the brain, causing a sudden loss of blood flow. This blockage prevents oxygen and nutrients from reaching brain tissue, leading to the death of brain cells. Symptoms can include sudden numbness or weakness, especially on one side of the body, confusion, trouble speaking, or difficulty understanding speech. Other symptoms may involve vision problems, dizziness, or loss of balance and coordination. The effects of an ischemic stroke can vary widely depending on the location and extent of the brain affected. Immediate medical attention is crucial to minimize brain damage and improve outcomes.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-504573-20-00Protocol code69HCL20_0403Estimated enrolment20 patientsSponsorHospices Civils De Lyon

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).